- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05150210
SP Thoracic IDE Study
A Prospective, Multi-Center Investigation of the da Vinci SP Surgical System in Pulmonary and Lobectomy for Benign and Malignant Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary performance:
The primary endpoint will be assessed as the ability to complete the planned da Vinci SP-assisted thoracic procedure without conversion to an alternate approach. Conversion to an alternate approach comprises undocking of the da Vinci SP to complete the planned procedures using other methods, such as open, VATS, or multiport robotic (da Vinci SI or X/Xi)
Primary Safety:
The primary safety endpoint will be assessed as the incidence of all intra-operative and post-operative adverse events that occur through the 30-day follow-up period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ling Lin
- Email: ling.lin@intusurg.com
Study Contact Backup
- Name: Jennifer Mueller
- Phone Number: 510-552-9880
- Email: jennifer.mueller@intusurg.com
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Cedars-Sinai Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, United States, 10016
- NYU Langone Health
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 21 years
- BMI ≤ 35
- ASA ≤ 3
- Willing and able to provide a written informed consent
- Willing and able to comply with the study protocol requirements including follow-up examinations at 14 days and 30 days post-operatively, and post-market long term follow-up on an annual basis through 5 years
Lobectomy Inclusion Criteria:
- Clinical stage I or II primary lung cancer or other suspected lung malignancy; or benign lung disease requiring resection; primary tumor ≤ 5cm diameter
Thymectomy Inclusion Criteria:
- Masaoka clinical stage I or II thymoma; or thymectomy for myasthenia gravis; thymic mass ≤ 5 cm diameter
Exclusion Criteria:
- Clinical or radiological evidence of mediastinal or systemic metastatic disease
- Life expectancy < 6 months
- Subject with a known bleeding or clotting disorder
- Subjects actively receiving therapeutic-dose anticoagulation or anti-platelet medications at the time of operation
- Uncontrolled systemic illness 6 months prior to planned surgical procedure including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Previous chemotherapy, immunotherapy and/or radiation therapy for treatment of the cancer to be resected
- Subject has a contraindication for general anesthesia or surgery
- Subjects under active immunomodulatory or immunosuppressive regimen (e.g. transplant patient, high-dose steroid requirement) within 30 days prior to the planned surgical procedure. For myasthenia patients, if steroids are weaned down to prednisone ≤ 5 mg/day prior to day of surgery, the patient may be enrolled
- Previous sternotomy
- Subject belongs to vulnerable population
- Subject is pregnant or suspected to be pregnant or breastfeeding
Lobectomy Exclusion Criteria:
- Tumor involving carina or any airway requiring sleeve resection, bronchoplasty
- Tumor requiring resection of local structures (e.g. chest wall) or extended resection such as bilobectomy
- History of pulmonary hypertension
- Previous ipsilateral thoracic surgery or radiotherapy
Thymectomy Exclusion Criteria:
- Uncontrolled myasthenia gravis symptoms at the time of scheduled surgery
- Tumor requiring resection of local structures (except pericardium)
- Confirmed thymic carcinoma
Intraoperative Exclusion Criteria:
- Anatomy determined intra-operatively to be unsuitable for minimally invasive surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SP Surgical System
Pulmonary lobectomy and thymectomy procedures will be performed by da Vinci SP Surgical System.
|
da Vinci SP Surgical System, instruments, and accessories in pulmonary lobectomy and thymectomy for benign and malignant disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Conversion
Time Frame: Intra-operative period
|
Performance defined as the ability to complete the planned da Vinci SP-assisted pulmonary lobectomy and thymectomy procedures without conversion to an alternate approach
|
Intra-operative period
|
Adverse Event Rate
Time Frame: Intra-operative through the 30 days follow-up period
|
Safety defined as the incidence of all intra-operative and post-operative adverse events that occur through the 30-day follow-up period.
|
Intra-operative through the 30 days follow-up period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Rice, MD, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphatic Diseases
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Thoracic Neoplasms
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Nervous System Neoplasms
- Neoplasms, Complex and Mixed
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Thymus Neoplasms
- Lung Diseases
- Thymoma
- Myasthenia Gravis
Other Study ID Numbers
- SP Thoracic IDE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thymoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Thymoma AJCC v8 | Stage IIIA Thymoma AJCC v8 | Stage IIIB Thymoma AJCC v8 | Stage IV Thymoma AJCC v8 | Stage IVA Thymoma AJCC v8 | Stage IVB Thymoma AJCC v8 | Unresectable Thymic CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedInvasive Thymoma and Thymic Carcinoma | Recurrent Thymoma and Thymic Carcinoma | Stage III Thymoma | Stage IVA Thymoma | Stage IVB ThymomaUnited States
-
Tiziana Life Sciences LTDTerminatedMalignant ThymomaUnited States, Italy
-
Yale UniversityWithdrawn
-
Prof. Dr. Berthold SchalkeCrolll GmbhCompletedPrimary Inoperable Thymoma | Local Recurrent ThymomaGermany
-
Tang-Du HospitalRecruitingThymoma and Thymic CarcinomaChina
-
Peng LiuNot yet recruitingHistological or Cytological Confirmed Stage Ⅲ and Ⅳa ThymomaChina
-
Armando Santoro, MDCompletedThymoma and Thymic CarcinomaItaly
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...RecruitingThymic Carcinoma | Type B3 ThymomaItaly
-
Jian ChenRecruitingCarbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, ChemotherapyChina
Clinical Trials on Robotic-Assisted Surgery
-
Intuitive SurgicalActive, not recruitingColorectal Cancer | Benign or Malignant Rectal or Colon TumorsUnited States, Korea, Republic of
-
Distalmotion SARecruitingHysterectomy | Partial Nephrectomy | Right ColectomySwitzerland, France, Germany
-
Hadassah Medical OrganizationUnknownVertebral Body AugmentationIsrael
-
Intuitive SurgicalRecruiting
-
Intuitive SurgicalWithdrawn
-
M.D. Anderson Cancer CenterCompletedBladder CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)SuspendedDisease or DisorderUnited States
-
Agenzia di Tutela della Salute della Città Metropolitana...Fondazione IRCCS Istituto Nazionale dei Tumori, Milano; Fondazione IRCCS Ca... and other collaboratorsNot yet recruiting
-
St. Joseph's Healthcare HamiltonUniversity of Florida; St Vincent's Hospital Melbourne; University of Toronto... and other collaboratorsRecruitingNon-small Cell Lung Cancer | Thoracic SurgeryCanada
-
Aesculap AGB.Braun Surgical SARecruiting